HRP20230701T1 - Modulatori za trex1 - Google Patents
Modulatori za trex1 Download PDFInfo
- Publication number
- HRP20230701T1 HRP20230701T1 HRP20230701TT HRP20230701T HRP20230701T1 HR P20230701 T1 HRP20230701 T1 HR P20230701T1 HR P20230701T T HRP20230701T T HR P20230701TT HR P20230701 T HRP20230701 T HR P20230701T HR P20230701 T1 HRP20230701 T1 HR P20230701T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- phenyl
- halo
- membered
- optionally
- Prior art date
Links
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 44
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 30
- 125000001475 halogen functional group Chemical group 0.000 claims 22
- 125000000623 heterocyclic group Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- -1 phenyl pyrazolyl Chemical group 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000005959 diazepanyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Amplifiers (AREA)
- Plural Heterocyclic Compounds (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Burglar Alarm Systems (AREA)
Claims (15)
1. Spoj sa formulom I:
[image]
ili njegova farmaceutski prihvatljiva sol, pri čemu:
R1 je vodik, (C1-C4)alkil, halo(C1-C4)alkil, 3- do 4-člani cikloalkil, -ORf, - SRf, ili -NReRf;
R2 je vodik, (C1-C4)alkil, halo(C1-C4)alkil, ili 3- do 4-člani cikloalkil;
X je veza, NR3, O, S, ili (C1-C4)alkilen, pri čemu je spomenuti (C1-C4)alkilen izborno supstituiran sa 1 do 2 skupine izabrane iz R4;
R3 je vodik, (C1-C4)alkil, -C(O)Rd, ili -C(S) Rd;
R4 je halo, (C1-C4)alkil, fenil, -NHC(O)ORa, -NHC(S)ORa, -C(O)Rb,-NHC(O)NH Rg, - NHC(S)NHRg, -NHS(O)2NHRg, -C(S)Rb, S(O)2Rc, S(O)Rc, -C(O)ORd, -C(S)ORd, -C(O)NHRe, - C(S)NHRe, -NHC(O)Rd, -NHC(S)Rd, -ORe, -SRe, -O(C1-C4)alkilORe, ili -NReRf, pri čemu spomenuti fenil za R4 je izborno supstituiran sa 1 ili 2 skupine izabrane iz halo, (C1-C4)alkil, halo(C1-C4)alkil, (C1-C4)alkoksi, i halo(C1-C4)alkoksi;
Prsten A je fenil, 5- do 6-člani heteroaril, 4- do 7-člani heterociklil, ili 3- do 7-člani cikloalkil, od kojih je svaki izborno i neovisno supstituiran sa 1 ili 2 skupine izabrane iz R5;
R5je (C1-C4)alkil, halo(C1-C4)alkil, halo(C1-C4)alkoksi, halo, fenil, -NHC(O)ORa, -NHC(S)ORa, -C(O)Rb,-NHC(O)NHRg, -NHC(S)NHRg, -NHS(O)2NHRg, -C(S)Rb, S(O)2Rc, S(O)Rc, -C(O)ORd, -C(S)ORd, -C(O)NReRf, -C(S)NHRe, -NHC(O)Rd, -NHC(S)Rd, -ORe, -SRe, - O(C1-C4)alkilORe, -NReRf, 4- do 6-člani heteroaril, ili 4- do 7-člani heterociklil, pri čemu spomenuti fenil za R5 je izborno supstituiran sa 1 ili 2 skupine izabrane iz Rg, a spomenuti (C1-C4)alkil za R5 je izborno supstituiran sa 1 ili 2 skupine izabrane iz ORh, -NRjRk, fenila, i 5- do 6-članog heteroarila, pri čemu su spomenuti 4- do 7-člani heterociklil i 4- do 6-člani heteroaril svaki izborno i neovisno supstituirani sa 1 ili 2 skupine izabrane iz Rm, i pri čemu su spomenuti fenili i 5- do 6-člani heteroaril opcionih supstituenata sa spiska za (C1-C4)alkil u R5 svaki izborno i neovisno supstituiran sa 1 ili 2 skupine izabrane iz Rg;
Rg, Rh, Rj, Rk, i Rm su svaki neovisno vodik, halo, (C1-C4)alkil, halo(Ci- C1-C4)alkil, (C1C4)alkoksi, halo(C1-C4)alkoksi, fenil, -(C1-C4)alkilfenil, 3- do 4-člani cikloalkil, 4- do 6-člani heteroaril, ili 4- do 7-člani heterociklil, i pri čemu spomenuti 4- do 7-člani heterociklil za Rg, Rh, Rj i Rk je još izborno supstituiran sa =O,
Ra, Rb, Rc, Rd, Re i Rf su svaki neovisno vodik, halo, (C1-C4)alkil, halo(C1-C4)alkil, (C1-C4) alkoksi, halo(C1-C4)alkoksi, fenil, 3- do 4-člani cikloalkil, 4-do 6-člani heteroaril, ili 4- do 7-člani heterociklil, pri čemu i) spomenuti (C1-C4)alkil za Ra, Rb, Rc, Rd, Re i Rf jeste izborno supstituiran sa 1 ili 2 skupine izabrane iz fenila, - ORh, -NRjRk; ii) pri čemu su spomenuti fenil, 4- do 6-člani heteroaril, i ) 4- do 7-člani heterociklil za Ra, Rb, Rc, Rd, Re, i Rf svaki izborno i neovisno supstituirani sa 1 ili 2 skupine izabrane iz Rg, i iii) spomenuti 4- do 7-člani heterociklil za Ra, Rb, Rc, Rd, Re, i Rf je dodatno izborno supstituiran sa =O.
2. Spoj iz patentnog zahtjeva 1, pri čemu taj spoj je iz Formule II:
[image]
ili njegova farmaceutski prihvatljiva sol.
3. Spoj iz patentnog zahtjeva 1 ili 2, i/ili njegova farmaceutski prihvatljiva sol, pri čemu R2 je (C1-C4) alkil.
4. Spoj iz bilo kojeg od patentnih zahtjeva 1 do 3, ili njegova farmaceutski prihvatljiva sol, pri čemu prsten A je fenil, piridil, pirazolil, ciklopropil, ciklobutil, azetidinil, ili piperidinil, od kojih je svaki izborno i neovisno supstituiran sa jednom ili dvije R5.
5. Spoj iz bilo kog od patentnih zahtjeva 1 do 3, ili njegova farmaceutski prihvatljiva sol, pri čemu prsten A je triazolil, pirolidinil, diazepanil, ili piperazinil, od koji je svaki izborno i neovisno supstituirani sa jednom ili dvije R5.
6. Spoj iz bilo kojeg od patentnih zahtjeva 1 do 5, ili njegova farmaceutski prihvatljiva sol, pri čemu R5 je (C1-C4)alkil, halo(C1-C4)alkil, halo(C1-C4)alkoksi, halo, fenil, -NHC(O)ORa, - C(O)Rb, S(O)2Rc, S(O)Rc, -C(O)ORd, -C(O)NReRf, -NHC(O)Rd, -ORe, -O(C1-C4)alkilORc, - NReRf, 4- do 6-člani heteroaril, ili 4- do 7-člani heterociklil, pri čemu spomenuti fenil za R5 je izborno supstituiran sa 1 ili 2 skupine izabrane iz Rg, a spomenuti (C1-C4)alkil za R5 je izborno supstituiran sa 1 ili 2 skupine izabrane iz -ORh, -NRjRk, fenila, i 5- do 6-člani heteroaril, pri čemu su spomenuti 4- do 6-člani heteroaril i 4- do 7-člani heterociklil svaki izborno i neovisno supstituirani sa 1 ili 2 skupine izabrane iz Rm, i pri čemu su spomenuti fenil i 5- do 6-člani heteroaril opcioni supstituenti na spisku za (C1-C4)alkil u R5 svaki izborno i neovisno supstituirani sa 1 ili 2 skupine izabrane iz Rg;
Ra je (C1-C4)alkil izborno supstituiran sa fenilom;
Rb je (C1-C4)alkil, fenil, 5- do 6-člani heteroaril ili 4- do 7-člani heterociklil, pri čemu je spomenuti (C1-C4)alkil izborno supstituiran sa 1 ili 2 skupine izabrane iz fenila, -ORh, i -NRjRk, pri čemu su spomenuti fenil, 5- do 6-člani heteroaril, i 4- do 7-člani heterociklil svaki izborno i neovisno supstituirani sa 1 ili 2 skupine izabrane iz Rg, i pri čemu je spomenuti 4- do 7-člani heterociklil dodatno izborno supstituiran i sa =O;
svaka Rc je neovisno fenil ili (C1-C4)alkil;
svaka Rd je vodik ili (C1-C4)alkil;
svaka Re je neovisno vodik ili (C1-C4)alkil izborno supstituiran sa ORh;
svaka Rf je neovisno vodik, (C1-C4)alkil, fenil 3- do 4-člani cikloalkil, 4-do 6-člani heteroaril, ili 5- do 6-člani heterociklil, pri čemu su spomenuti fenil, 3- do 4-člani cikloalkil, 4- do 6-člani heteroaril, i 5- do 6-člani heterociklil svaki izborno i neovisno supstituirani sa Rg; a svaki Rg je neovisno (C1-C4)alkil, halo(C1-C4)alkil, (C1-C4)alkoksi, halo(C1-C4)alkoksi, ili halo;
svaki Rh je vodik, (C1-C4)alkil, ili -( C1-C4)alkilfenil;
svaki Rj je neovisno vodik ili (C1-C4)alkil;
svaki Rk je neovisno vodik, (C1-C4)alkil, ili 3- do 4-člani cikloalkil; i svaki Rm je (C1-C4)alkil.
7. Spoj iz bilo kojeg od patentnih zahtjeva 1 do 6, ili njegova farmaceutski prihvatljiva sol, pri čemu R5 je (C1-C4)alkil, halo(C1-C4)alkil, halo, fenil, - NHC(O)ORa, -C(O)Rb, S(O)2Rc, - C(O)ORd, -C(O)NReRf, -NHC(O)Rd, -O(C1-C4)alkilORe, -NReRf, 4- do 6-člani heteroaril, ili 5- do 6-člani heterociklil, pri čemu je spomenuti (C1-C4)alkil za R5 izborno supstituiran sa -ORh, fenilom, ili 5- do 6-članim heteroarilom, a spomenuti 4- do 6-člani heteroaril i 5- do 6-člani heterociklil su svaki izborno i neovisno supstituirani sa 1 ili 2 skupine izabrane iz Rm, i pri čemu su spomenuti fenil i 5- do 6-člani heteroaril opcioni supstituenti na spisku za (C1-C4)alkil u R5 svaki izborno i neovisno supstituirani sa 1 ili 2 skupine izabrane iz Rg.
8. Spoj iz bilo kojeg od patentnih zahtjeva 1 do 7, ili njegova farmaceutski prihvatljiva sol, pri čemu je svaki Rf neovisno vodik, (C1-C4)alkil, fenil pirazolil, piridinil, tetrahidropiranil, piperidinil, pri čemu spomenuti fenil pirazolil, piridinil, tetrahidropiranil, i piperidinil jesu svaki izborno i neovisno supstituirani sa (C1-C4)alkilom; i svaki Rg je neovisno (C1-C4)alkil, (C1-C4)alkoksi, ili halo.
9. Spoj iz bilo kojeg od patentnih zahtjeva 1 do 8, ili njegova farmaceutski prihvatljiva sol, pri čemu je Rb (C1-C4)alkil, fenil, 5- do 6-člani heteroaril ili 4- do 7-člani heterociklil, pri čemu su spomenuti fenil i 5- do 6-člani heteroaril za Rb svaki izborno i neovisno supstituirani sa 1 ili 2 skupine izabrane iz halo i (C1-C4)alkoksi, pri čemu spomenuti 4- do 7-člani heterociklil za Rb jeste izborno supstituiran sa =O, i pri čemu spomenuti (C1-C4)alkil za Rb jeste izborno supstituiran sa 1 ili 2 skupine izabrane iz fenila, -ORh, i - NRjRk.
10. Spoj iz bilo kojeg od patentnih zahtjeva 1 do 9, ili njegova farmaceutski prihvatljiva sol, pri čemu je svaka Rk neovisno vodik ili (C1-C4) alkil.
11. Spoj iz patentnog zahtjeva 1 do 10, i njegova farmaceutski prihvatljiva sol, pri čemu je X nesupstituirani (C1-C4) alkilen.
12. Spoj iz bilo kojeg od patentnih zahtjeva 1 do 11, ili njegova farmaceutski prihvatljiva sol, pri čemu R4 je fenil ili -NHC(O)ORa.
13. Spoj iz bilo kojeg od patentnih zahtjeva 1 do 12, ili njegova farmaceutski prihvatljiva sol, pri čemu je X veza ili CH2.
14. Farmaceutski pripravak koja obuhvaća spoj iz bilo kojeg od patentnih zahtjeva 1 do 13, ili njegova farmaceutski prihvatljiva sol, i farmaceutskih prihvatljiv nosač.
15. Spoj iz bilo kojeg od patentnih zahtjeva 1 do 14, ili njegova farmaceutski prihvatljiva sol, za upotrebu za liječenje raka.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776031P | 2018-12-06 | 2018-12-06 | |
| EP19828476.2A EP3891145B1 (en) | 2018-12-06 | 2019-12-06 | Modulators of trex1 |
| PCT/US2019/064825 WO2020118133A1 (en) | 2018-12-06 | 2019-12-06 | Modulators of trex1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230701T1 true HRP20230701T1 (hr) | 2023-10-13 |
Family
ID=69024702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230701TT HRP20230701T1 (hr) | 2018-12-06 | 2019-12-06 | Modulatori za trex1 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20220017502A1 (hr) |
| EP (1) | EP3891145B1 (hr) |
| JP (1) | JP7471297B2 (hr) |
| KR (1) | KR20210102310A (hr) |
| CN (1) | CN113396149A (hr) |
| AU (1) | AU2019395005A1 (hr) |
| BR (1) | BR112021010919A2 (hr) |
| CA (1) | CA3122093A1 (hr) |
| CL (1) | CL2021001461A1 (hr) |
| CO (1) | CO2021008816A2 (hr) |
| CY (1) | CY1126082T1 (hr) |
| DK (1) | DK3891145T3 (hr) |
| EA (1) | EA202191519A1 (hr) |
| ES (1) | ES2949999T3 (hr) |
| FI (1) | FI3891145T3 (hr) |
| HR (1) | HRP20230701T1 (hr) |
| HU (1) | HUE062866T2 (hr) |
| IL (1) | IL283672A (hr) |
| LT (1) | LT3891145T (hr) |
| MA (1) | MA54386B1 (hr) |
| MX (1) | MX2021006695A (hr) |
| PE (1) | PE20212070A1 (hr) |
| PL (1) | PL3891145T3 (hr) |
| PT (1) | PT3891145T (hr) |
| RS (1) | RS64336B1 (hr) |
| SG (1) | SG11202105772SA (hr) |
| SI (1) | SI3891145T1 (hr) |
| WO (1) | WO2020118133A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220035916A (ko) * | 2019-07-23 | 2022-03-22 | 콘스텔레이션 파마슈티칼스, 인크. | Trex1의 조절제 |
| WO2022031640A1 (en) * | 2020-08-04 | 2022-02-10 | Wake Forest University Health Sciences | Trex1 inhibitors and uses thereof |
| CN117545754A (zh) * | 2021-04-26 | 2024-02-09 | 星座制药公司 | Trex1的调节剂 |
| CN117561251A (zh) * | 2021-05-05 | 2024-02-13 | 星座制药公司 | Trex1的调节剂 |
| WO2023137030A1 (en) * | 2022-01-11 | 2023-07-20 | Constellation Pharmaceuticals, Inc. | Modulators of trex1 |
| WO2023156386A2 (en) * | 2022-02-16 | 2023-08-24 | Duke Street Bio Limited | Pharmaceutical compound |
| WO2023250439A1 (en) * | 2022-06-22 | 2023-12-28 | Tempest Therapeutics, Inc. | Trex1 inhibitors and uses thereof |
| WO2024061300A1 (en) * | 2022-09-22 | 2024-03-28 | Insilico Medicine Ip Limited | Inhibitors of trex1 and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI409070B (zh) * | 2005-11-04 | 2013-09-21 | Hydra Biosciences Inc | 用於調節ｔｒｐｖ３功能之化合物 |
| WO2009106561A1 (en) * | 2008-02-27 | 2009-09-03 | Biovitrum Ab (Publ) | Pyrazine compounds for treating gpr119 related disorders |
| WO2009147079A1 (en) * | 2008-06-02 | 2009-12-10 | Janssen Pharmaceutica Nv | 3,4-dihydropyrimidine trpa1 antagonists |
| MX2012003400A (es) * | 2009-10-02 | 2012-04-10 | Sanofi Sa | Uso de compuestos con actividad inhibidora de sglt - 1/sglt - 2 para producir medicamentos para el tratamiento de enfermedades oseas. |
| WO2011107494A1 (de) * | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2685982B1 (en) * | 2011-03-17 | 2017-07-05 | Bristol-Myers Squibb Company | Pyrrolopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases |
-
2019
- 2019-12-06 LT LTEPPCT/US2019/064825T patent/LT3891145T/lt unknown
- 2019-12-06 MX MX2021006695A patent/MX2021006695A/es unknown
- 2019-12-06 AU AU2019395005A patent/AU2019395005A1/en active Pending
- 2019-12-06 SI SI201930577T patent/SI3891145T1/sl unknown
- 2019-12-06 EP EP19828476.2A patent/EP3891145B1/en active Active
- 2019-12-06 PL PL19828476.2T patent/PL3891145T3/pl unknown
- 2019-12-06 CN CN201980091375.4A patent/CN113396149A/zh active Pending
- 2019-12-06 SG SG11202105772SA patent/SG11202105772SA/en unknown
- 2019-12-06 PE PE2021000822A patent/PE20212070A1/es unknown
- 2019-12-06 DK DK19828476.2T patent/DK3891145T3/da active
- 2019-12-06 BR BR112021010919-6A patent/BR112021010919A2/pt unknown
- 2019-12-06 HU HUE19828476A patent/HUE062866T2/hu unknown
- 2019-12-06 ES ES19828476T patent/ES2949999T3/es active Active
- 2019-12-06 EA EA202191519A patent/EA202191519A1/ru unknown
- 2019-12-06 MA MA54386A patent/MA54386B1/fr unknown
- 2019-12-06 JP JP2021531909A patent/JP7471297B2/ja active Active
- 2019-12-06 HR HRP20230701TT patent/HRP20230701T1/hr unknown
- 2019-12-06 FI FIEP19828476.2T patent/FI3891145T3/fi active
- 2019-12-06 CA CA3122093A patent/CA3122093A1/en active Pending
- 2019-12-06 KR KR1020217020940A patent/KR20210102310A/ko unknown
- 2019-12-06 WO PCT/US2019/064825 patent/WO2020118133A1/en unknown
- 2019-12-06 PT PT198284762T patent/PT3891145T/pt unknown
- 2019-12-06 US US17/311,526 patent/US20220017502A1/en active Pending
- 2019-12-06 RS RS20230531A patent/RS64336B1/sr unknown
-
2021
- 2021-06-03 IL IL283672A patent/IL283672A/en unknown
- 2021-06-03 CL CL2021001461A patent/CL2021001461A1/es unknown
- 2021-07-02 CO CONC2021/0008816A patent/CO2021008816A2/es unknown
-
2023
- 2023-07-11 CY CY20231100328T patent/CY1126082T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3891145B1 (en) | 2023-04-12 |
| MX2021006695A (es) | 2021-09-23 |
| EA202191519A1 (ru) | 2021-10-27 |
| MA54386B1 (fr) | 2023-08-31 |
| ES2949999T3 (es) | 2023-10-04 |
| RS64336B1 (sr) | 2023-08-31 |
| PT3891145T (pt) | 2023-07-18 |
| SI3891145T1 (sl) | 2023-11-30 |
| JP7471297B2 (ja) | 2024-04-19 |
| FI3891145T3 (fi) | 2023-07-18 |
| LT3891145T (lt) | 2023-08-10 |
| SG11202105772SA (en) | 2021-06-29 |
| JP2022510431A (ja) | 2022-01-26 |
| WO2020118133A1 (en) | 2020-06-11 |
| HUE062866T2 (hu) | 2023-12-28 |
| CL2021001461A1 (es) | 2021-12-17 |
| EP3891145A1 (en) | 2021-10-13 |
| CN113396149A (zh) | 2021-09-14 |
| DK3891145T3 (da) | 2023-07-24 |
| US20220017502A1 (en) | 2022-01-20 |
| IL283672A (en) | 2021-07-29 |
| BR112021010919A2 (pt) | 2021-08-24 |
| KR20210102310A (ko) | 2021-08-19 |
| CA3122093A1 (en) | 2020-06-11 |
| PL3891145T3 (pl) | 2023-08-07 |
| AU2019395005A1 (en) | 2021-06-17 |
| MA54386A (fr) | 2021-10-13 |
| CY1126082T1 (el) | 2023-11-15 |
| PE20212070A1 (es) | 2021-10-26 |
| CO2021008816A2 (es) | 2021-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230701T1 (hr) | Modulatori za trex1 | |
| AU2017382258B2 (en) | Tetrahydro imidazo(4,5-c)pyridine derivatives as PD-L1 internalization inducers | |
| RS52862B (en) | IMIDASO [1,2-A] Pyridine Compounds as Tyrosine Kinase Receptor Inhibitors | |
| HRP20200632T1 (hr) | Derivati piridopirazina i naftiridina za liječenje raka | |
| HRP20210365T1 (hr) | Dna-pk inhibitori | |
| ES2749713T3 (es) | Compuestos de indol e indazol sustituidos con 3-ciclohexenilo y ciclohexilo como inhibidores de RORgammaT y usos de los mismos | |
| ES2887578T3 (es) | Compuestos de amida para el tratamiento de infecciones por VIH | |
| HRP20210190T1 (hr) | Heterociklični spojevi kao imunomodulatori | |
| AR104897A1 (es) | Compuestos de quelatos de gadolinio para usar en imágenes de resonancia magnética | |
| HRP20211801T1 (hr) | Derivati kinolin-2-ona | |
| WO2014026329A1 (en) | N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof | |
| AR047890A1 (es) | Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3 | |
| MY144048A (en) | Chemical compound | |
| JP2010524932A5 (hr) | ||
| AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
| PE20171177A1 (es) | Compuestos aminopirimidinilo inhibidores de jak | |
| CA2579915A1 (en) | Indole derivatives and their use as inhibitors of p53-mdm2 interaction | |
| JP2015514808A5 (hr) | ||
| RU2016135922A (ru) | Терапевтические соединения и композиции | |
| WO2014026330A1 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| WO2015004566A3 (en) | Liquid bisacylphosphine oxide photoinitiator | |
| NO20062269L (no) | Pyridin-karboksylsyrederivater som glucokinasemodulatorer | |
| JP2017519027A5 (hr) | ||
| CN110896634A (zh) | 作为atf4抑制剂用于治疗癌症和其它疾病的2-(4-氯苯氧基)-n-((1-(2-(4-氯苯氧基)乙炔氮杂环丁烷-3-基)甲基)乙酰胺衍生物和相关化合物 | |
| JP2016531858A5 (hr) |